Sec Form 3/A Filing - Mahoney Robert Patrick @ Comera Life Sciences Holdings, Inc. - 2022-05-19

FORM 3/A Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person Mahoney Robert Patrick 2. Issuer Name and Ticker or Trading Symbol Comera Life Sciences Holdings, Inc. [ CMRA] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director _____ 10% Owner X __ Officer (give title below) _____ Other (specify below) Chief Scientific Officer (Last) (First) (Middle) C/O COMERA LIFE SCIENCES HOLDINGS, INC., 12 GILL STREET, SUITE 4650 3. Date of Earliest Transaction (MM/DD/YY) 05/19/2022 (Street) WOBURN, MA01801 4. If Amendment, Date Original Filed (MM/DD/YY) 05/20/2022 6. Individual or Joint/Group Filing (Check Applicable Line) __ X __ Form filed by One Reporting Person _____ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Stock Option (Right to Buy) ( 1 ) $ 0.59 ( 2 ) 06/08/2031 Common Stock 10,067 D Stock Option (Right to Buy) ( 1 ) $ 0.59 ( 3 ) 12/14/2031 Common Stock 15,422 D

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other Mahoney Robert Patrick C/O COMERA LIFE SCIENCES HOLDINGS, INC. 12 GILL STREET, SUITE 4650 WOBURN, MA01801 Chief Scientific Officer Signatures /s/ Ryan M. Rourke Reed, Attorney-in-Fact 02/14/2023 Signature of Reporting Person Date

Explanation of Responses:

( 1 )This Form 3/A is being filed to correct information previously disclosed on the original Form 3 filed by the reporting person on May 20, 2022, including disclosing the stock option grant as a single grant, the Date Exercisable, Expiration Date, Amount or Number of Shares, Exercise Price and vesting schedule of each grant. This Form 3/A also includes the reporting person's power-of-attorney. ( 2 )This option was issued pursuant to the terms of a business combination agreement involving the issuer and Comera Life Sciences, Inc. in exchange for a comparable option previously issued by such company on June 8, 2021. The option vests in 36 equal monthly installments beginning June 8, 2021. ( 3 )This option was issued pursuant to the terms of a business combination agreement involving the issuer and Comera Life Sciences, Inc. in exchange for a comparable option previously issued by such company on December 14, 2021. 25% of the option vests or vested on October 1, 2021 and in equal monthly installments thereafter for 36 months.

Remarks: Exhibit 24 Power of Attorney filed herewith.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.